Abstract
Comprehensive research of the pathogenesis of malignant lymphoma has resulted in the introduction of some novel concepts of treatment strategy. The cell of origin (COO) of diffuse large B cell lymphoma (DLBCL) can be identified using gene expression profiling and then becomes the most critical indicator of DLBCL. The stratification by COO is essential when incorporating molecule-targeting agents into DLBCL treatment. The era of tumor immunity has arrived. Lately, immune checkpoint inhibitors, adoptive cell immunotherapy, and other immune therapies have been transforming the management of malignant lymphoma. Now bench and bed have been getting engaged in the field of lymphoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
